| Assembly Actions - Lowercase Senate Actions - UPPERCASE |
|
|---|---|
| Jan 08, 2020 | referred to health |
| Jun 05, 2019 | print number 6757a |
| Jun 05, 2019 | amend (t) and recommit to health |
| Mar 19, 2019 | referred to health |
Archive: Last Bill Status - In Assembly Committee
- Introduced
- In Committee
- On Floor Calendar
- Passed Senate
- Passed Assembly
- Delivered to Governor
- Signed/Vetoed by Governor
Your Voice
Actions
Bill Amendments
Co-Sponsors
Jonathan Jacobson
Multi-Sponsors
William A. Barclay
A6757 - Details
A6757 - Bill Text download pdf
S T A T E O F N E W Y O R K
________________________________________________________________________
6757
2019-2020 Regular Sessions
I N A S S E M B L Y
March 19, 2019
___________
Introduced by M. of A. CUSICK -- Multi-Sponsored by -- M. of A. BARCLAY
-- read once and referred to the Committee on Health
AN ACT to amend the public health law and the penal law, in relation to
controlled substance analogues
THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:
Section 1. Section 3302 of the public health law is amended by adding
a new subdivision 44 to read as follows:
44. "CONTROLLED SUBSTANCE ANALOGUE" (A) MEANS A SUBSTANCE, THE CHEMI-
CAL STRUCTURE OF WHICH IS SUBSTANTIALLY SIMILAR TO THE CHEMICAL STRUC-
TURE OF A CONTROLLED SUBSTANCE LISTED IN SCHEDULE I OR II OF SECTION
THIRTY-THREE HUNDRED SIX OF THIS TITLE, AND WHICH EITHER:
(I) HAS A STIMULANT, DEPRESSANT OR HALLUCINOGENIC EFFECT ON THE
CENTRAL NERVOUS SYSTEM THAT MIMICS OR IS SIMILAR TO OR GREATER THAN THE
STIMULANT, DEPRESSANT OR HALLUCINOGENIC EFFECT ON THE CENTRAL NERVOUS
SYSTEM OF A CONTROLLED SUBSTANCE LISTED IN SCHEDULE I OR II OF SECTION
THIRTY-THREE HUNDRED SIX OF THIS TITLE; OR
(II) WITH RESPECT TO A PARTICULAR PERSON, IS A SUBSTANCE THAT SUCH
PERSON REPRESENTS OR INTENDS TO HAVE A STIMULANT, DEPRESSANT OR HALLUCI-
NOGENIC EFFECT ON THE CENTRAL NERVOUS SYSTEM THAT IS SUBSTANTIALLY SIMI-
LAR TO OR GREATER THAN THE STIMULANT, DEPRESSANT OR HALLUCINOGENIC
EFFECT ON THE CENTRAL NERVOUS SYSTEM OF A CONTROLLED SUBSTANCE LISTED IN
SCHEDULE I OR II OF SECTION THIRTY-THREE HUNDRED SIX OF THIS TITLE.
(B) SUCH TERM SHALL NOT INCLUDE:
(I) A CONTROLLED SUBSTANCE;
(II) ANY SUBSTANCE FOR WHICH THERE IS AN APPROVED NEW DRUG APPLICATION
BY THE FEDERAL FOOD AND DRUG ADMINISTRATION (FDA); OR
(III) WITH RESPECT TO A PARTICULAR PERSON, ANY SUBSTANCE, IF AN
EXEMPTION IS IN EFFECT FOR INVESTIGATIONAL USE FOR THAT PERSON, AS
PROVIDED BY 21 U.S.C. § 355, TO THE EXTENT CONDUCT WITH RESPECT TO THE
SUBSTANCE IS PURSUANT TO SUCH EXEMPTION.
EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
[ ] is old law to be omitted.
Co-Sponsors
Jonathan Jacobson
Karl Brabenec
Multi-Sponsors
William A. Barclay
A6757A (ACTIVE) - Details
A6757A (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K
________________________________________________________________________
6757--A
2019-2020 Regular Sessions
I N A S S E M B L Y
March 19, 2019
___________
Introduced by M. of A. CUSICK, JACOBSON -- Multi-Sponsored by -- M. of
A. BARCLAY -- read once and referred to the Committee on Health --
committee discharged, bill amended, ordered reprinted as amended and
recommitted to said committee
AN ACT to amend the public health law and the penal law, in relation to
fentanyl analogues
THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:
Section 1. Section 3302 of the public health law is amended by adding
a new subdivision 44 to read as follows:
44. "FENTANYL ANALOGUE" (A) MEANS ANY SUBSTANCE THAT IS STRUCTURALLY
RELATED TO FENTANYL BY ONE OR MORE OF THE FOLLOWING MODIFICATIONS:
(I) REPLACEMENT OF THE PHENYL PORTION OF THE PHENETHYL GROUP BY ANY
MONOCYCLE, WHETHER OR NOT FURTHER SUBSTITUTED IN OR ON THE MONOCYCLE;
(II) SUBSTATION IN OR ON THE PHENETHYL GROUP WITH ALKL, ALKENYL,
ALKOXYL, HYDROXYL, HALO, HALOALKYL, AMINO OR NITRO GROUPS;
(III) SUBSTITUTION IN OR ON THE PIPERIDINE RING WITH ALKYL, ALKENYL,
ALKOXYL, ESTER, ETHER, HYDROXYL, HALO, HALOALKYL, AMINO OR NITO GROUPS;
(IV) REPLACEMENT OF THE ANILINE RING WITH ANY AROMATIC MONOCYCLE
WHETHER OR NOT FURTHER SUBSTITUTED IN OR ON THE AROMATIC MONOCYLCE;
AND/OR
(V) REPLACEMENT OF THE N-PROPIONYL GROUP BY ANOTHER ACYL GROUP.
(B) SUCH TERM SHALL NOT INCLUDE:
(I) FENTANYL;
(II) ANY SUBSTANCE FOR WHICH THERE IS AN APPROVED NEW DRUG APPLICATION
BY THE FEDERAL FOOD AND DRUG ADMINISTRATION (FDA); OR
(III) WITH RESPECT TO A PARTICULAR PERSON, ANY SUBSTANCE, IF AN
EXEMPTION IS IN EFFECT FOR INVESTIGATIONAL USE FOR THAT PERSON, AS
PROVIDED BY 21 U.S.C. § 355, TO THE EXTENT CONDUCT WITH RESPECT TO THE
SUBSTANCE IS PURSUANT TO SUCH EXEMPTION.
EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD06553-03-9